Understanding and improving treatments for prostate cancer
Official title: SPORE in Prostate Cancer
Funded at Johns Hopkins University · NIH-10769303 · Data updated 2026-11-12
This study is looking into how prostate cancer grows and becomes harder to treat, with the goal of finding better treatments to help men with advanced prostate cancer live longer and healthier lives.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $2,190,123 |
| NIH project number | 1P50CA272391-01A1 |
| Project ID | NIH-10769303 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include men diagnosed with advanced or metastatic prostate cancer who have not responded well to existing therapies.
✕Less likely to help
Patients with early-stage prostate cancer or those who have not yet undergone treatment may not benefit from this research.
What this research studies
This research focuses on prostate cancer, the most common cancer diagnosed in men in the U.S. The project aims to explore the molecular mechanisms behind prostate cancer progression, particularly how changes in hormone regulation, DNA repair, and the immune environment contribute to treatment resistance. By leveraging insights gained from previous studies, the research seeks to develop more effective therapies that could improve survival rates for patients with advanced prostate cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for prostate cancer, potentially improving survival rates and quality of life for patients.
How similar studies have gone: Previous research has shown promise in understanding the molecular mechanisms of prostate cancer, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Denmeade, Samuel R — Johns Hopkins University
- Study coordinator: Denmeade, Samuel R
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.